Serum Levels of Advanced Glycation End Products (AGEs) are Inversely Associated with the Number and Migratory Activity of Circulating Endothelial Progenitor Cells in Apparently Healthy Subjects

Cardiovascular Therapeutics

Volumn 30, Issue 4, 2012, Pages 249-254

  Ueda, So ^a   Yamagishi, Sho ichi ^b   Matsui, Takanori ^b   Noda, Yoshihiro ^a   Ueda, Shin ichiro ^a   Jinnouchi, Yuko ^a   Sasaki, Ken ichiro ^a   Takeuchi, Masayoshi ^c   Imaizumi, Tsutomu ^a  

^a Department of Medicine Division of Cardiovascular Medicine   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGEs; Atherosclerosis; Diabetes; EPC

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD CHEMISTRY; CARDIOVASCULAR RISK; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SMOKING;

ADULT; ANTIGENS, CD34; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELL COUNT; CELL MOVEMENT; CELLS, CULTURED; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; SEX FACTORS; SMOKING; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84863499980     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00264.x     Document Type: Article

References (37)

1. Shantsila E, Watson T, Lip GYH. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007;49:741-752.
2. Werner N, Nickenig G. Clinical and therapeutical implications of EPC biology in atherosclerosis. J Cell Mol Med 2006;10:318-322.
3. Yamagishi S, Nakamura K, Matsui T. 2008. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr Med Chem 2008;15:172-177.
4. Kondo T, Hirose M, Kageyama K. Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscle Thromb 2009;16:532-538.
5. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Cir Res 2001;89:E1-E7.
6. Hill JM, Zalosm G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
7. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol 2005;45:1441-1448.
8. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab invest 1994;70:138-150.
9. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med 1995;46:223-234.
10. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. J Biol Chem 1991;18:11654-11660.
11. Grandhee S, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. J Biol Chem 1991;18:11649-11653.
12. Yamagishi S. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther Apher Dial 2009;13:534-539.
13. Schmidt AM, Stern D. Atherosclerosis and diabetes: The RAGE connection. Curr Atheroscler Rep 2000;5:430-436.
14. Yamagishi S, Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279-2299.
15. Gul A, Rahman MA, Salim A, Simjee SU. Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complications. Age 2008;30:303-309.
16. Kilhovd BK, Juutilainen A, Lehto S, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: A population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005;25:815-820.
17. Kilhovd BK, Juutilainen A, Lehto S, Rönnemaa T, Torjesen PA, Hanssen KF, Laakso M. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: A population-based 18 year follow-up study. Diabetologia 2007;50:1409-1417.
18. Kilhovd B, Juutilainen A, Lehto S, Rönnemaa T, Torjesen PA, Hanssen KF, Laakso M.Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis 2009;205:590-594.
19. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002;25:1055-1059.
20. Uribarri J, Stirban A, Sander D, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 2007;30:2579-2582.
21. Yamagishi S, Adachi H, Nakamura K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006;55:1227-1231.
22. Jinnouchi Y, Yamagishi S, Takeuchi M, Ishida S, Jinnouchi Y, Jinnouchi J, Imaizumi T. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006;6:191-193.
23. Hyogo H, Yamagishi S, Iwamoto K, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007;22:1112-1119.
24. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-228.
25. Kondo T, Hayashi M, Takeshita K, et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vas Biol 2004;24:1442-1447.
26. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;108:391-397.
27. Sasaki K, Heeschen C, Aicher A, et al. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci USA 2006;103:14537-14541.
28. Urich C, Dimmeler S. Endothelial progenitor cells. Characterization and role in vascular biology. Cir Res 2004;95:343-353.
29. Yamagishi S, Adachi H, Takeuchi M, et al. Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res 2007;39:845-848.
30. Nakamura K, Yamagishi S, Adachi H, et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 2008;24:109-114.
31. Urich C, Dimmeler S. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int 2005;67:1672-1676.
32. Petoumenos V, Nickenig G, Werner N. High density lipoprotein exerts vasculoprotection via endothelial progenitor cells. J Cell Mol Med 2009;13:4623-4635.
33. Yamagishi S, Matsui T, Adachi H, Takeuchi M. Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. Pharmcol Res 2008;61:103-107.
34. Nakamura K, Yamagishi SI, Matsui T, Adachi H, Takeuchi M, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med 2007;7:188-190.
35. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008;14:973-978.
36. Sun C, Liang C, Ren Y, et al. Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol 2009;104:42-49.
37. Liang C, Ren Y, Tan H, et al. Rosiglitazone via upregulation of Akt/eNOS pathways attenuate dysfunction of endothelial progenitor cells, induced by advanced glycation end products. Br J Pharmacol 2009;158:1865-1873.